Abstract
Background: Minimally invasive mitral valve surgery (mini-MVS) has become routine in some institutions. However, the data of mini-MVS in rheumatic disease is very limited. We conducted a study to evaluate the safety and efficacy of minimally invasive mitral valve replacement (MIMVR) for treating rheumatic mitral valve disease in Bach Mai hospital. Methods: From January 2018 - Deccembre 2020, 80 patients with rheumatic mitral valve disease underwent mitral valve replacement via right minithoracotomy at Vietnam National Heart Institute. We analyzed early postoperative outcomes, including 30-day mortality. Results: Our cohort included 22 (27.5%) males and 58 (72.5%), with mean age of 49.9 ± 9.5 years, left ventricular ejection fraction of 64.5 ± 7.3%, and New York Heart Association functional classification of 2.55 ± 0.53. Mean cardiopulmonary bypass time of 93.8 ± 17.9 min, and cross-clamp time of 61.9 ± 14.6 min. Mean mechanical ventilation time was 15.8 ± 24.7 hours, intensive care unit length of stay was 54.5 ± 79.9 hours, and hospital length of stay was 10.5 ± 4.7 days. No conversion to sternotomy was required and no cerebrovascular accidents occurred. Groin seroma occurred in 1 (4.4%) patient, haemothorax and pneumothorax in 7 (8.8%). 30-day mortality was 1.3%. Pre-discharge echocardiography revealed no residual gradient in all patients. Conclusions: Preliminary results for our minimally invasive mitral valve replacement in rheumatic diseases demonstrate early safety, with acceptable operative times and outcomes.
